Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
06:30am, Tuesday, 29'th Oct 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
09:00am, Thursday, 25'th Jul 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
03:17pm, Thursday, 09'th May 2024
GlycoMimetics, Inc. (NASDAQ:GLYC ) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
08:40am, Monday, 06'th May 2024
GlycoMimetics (NASDAQ: GLYC ) stock is taking a beating on Monday after the biotechnology company announced results from a Phase 3 clinical trial. Unfortunately for GLYC stockholders, this clinical t
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
07:00am, Thursday, 25'th Apr 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9,
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
07:00am, Wednesday, 27'th Mar 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics Can Become A Game Changer In Blood Cancers
05:47pm, Thursday, 21'st Mar 2024
GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor p
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
09:51am, Thursday, 21'st Mar 2024
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
07:00am, Wednesday, 13'th Mar 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
07:00am, Monday, 26'th Feb 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Heal
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 12'th Feb 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on Februar
GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
01:04pm, Tuesday, 30'th Jan 2024
GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer. The company's most advanced project, Uproleselan, has recently shown promising results in a p
